THOUSAND OAKS, Calif.,
Sept. 16, 2020 /PRNewswire/ -- Amgen
(NASDAQ:AMGN) will host two webcast calls for the investment
community in conjunction with the European Society for Medical
Oncology (ESMO) 2020 Virtual Congress. On Sunday, Sept. 20,
2020, at 11:00 a.m. PDT, David
M. Reese, M.D., executive vice president of Research and
Development at Amgen, along with members of Amgen's
clinical development team and clinical investigators, will discuss
Phase 1 data being presented on the Company's investigational
KRASG12C inhibitor sotorasib (AMG 510). On
Monday, Sept. 21, at 1:00 p.m. PDT, David M.
Reese, M.D., along with members of Amgen's clinical
development team, will discuss the Phase 1 data being presented on
the Company's investigational half-life extended bispecific T-cell
engager (BiTE®) immuno-oncology therapy targeting
prostate-specific membrane antigen (PSMA).
Live audio of the investor call will be broadcast over the
internet simultaneously and will be available to members of the
news media, investors and the general public.
The webcast, as with other selected presentations regarding
developments in Amgen's business given at certain investor and
medical conferences, can be accessed on Amgen's website,
www.amgen.com, under Investors. Information regarding presentation
times, webcast availability and webcast links are noted on Amgen's
Investor Relations Events Calendar. The webcast will be archived
and available for replay for at least 90 days after the
event.
About Amgen
Amgen is committed to
unlocking the potential of biology for patients suffering from
serious illnesses by discovering, developing, manufacturing and
delivering innovative human therapeutics. This approach begins by
using tools like advanced human genetics to unravel the
complexities of disease and understand the fundamentals of human
biology.
Amgen focuses on areas of high unmet medical need and leverages
its expertise to strive for solutions that improve health outcomes
and dramatically improve people's lives. A biotechnology pioneer
since 1980, Amgen has grown to be one of the world's leading
independent biotechnology companies, has reached millions of
patients around the world and is developing a pipeline of medicines
with breakaway potential.
For more information, visit www.amgen.com and follow
us on www.twitter.com/amgen.
CONTACT: Amgen, Thousand Oaks
Megan Fox, 805-447-1423 (media)
Trish Rowland,
805-447-5631(media)
Arvind Sood, 805-447-1060
(investors)
View original content to download
multimedia:http://www.prnewswire.com/news-releases/amgen-to-webcast-investor-calls-at-esmo-2020-301132566.html
SOURCE Amgen